SurModics (SRDX) has been on a downward spiral lately with significant selling pressure. After declining 6.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock i ...

For the quarter ended June 2024, SurModics (SRDX) reported revenue of $30.34 million, down 42.2% over the same period last year. EPS came in at -$0.27, compared to $0.52 in the year-ago quarter. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Here is how SurModics performed in the just reported quarter in terms of the m ...

This quarterly report represents an earnings surprise of 12.90%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.36 per share when it actually produced earnings of $0.07, delivering a surprise of 119.44%. SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarter ...

财务业绩 - 公司第三季度收入为3.03亿美元，同比下降42%[128] - 第三季度SurVeil DCB许可费收入为1.13亿美元，同比下降96%[128] - 第三季度医疗器械分部收入为2.34亿美元，同比下降49%[128] - 第三季度体外诊断分部收入为6960万美元，同比增长8%[129] - 前三季度收入为9.29亿美元，同比下降11%[128] - 前三季度SurVeil DCB许可费收入为3190万美元，同比下降89%[129] - 前三季度医疗器械分部收入为7.18亿美元，同比下降15%[129] - 前三季度体外诊断分部收入为2.11亿美元，同比增长6%[129] 并购相关 - 公司于2024年5月28日与BCE Parent, LLC签订合并协议，以每股43美元的现金价格收购公司[118] - 公司在第三季度和前三季度共计发生290万美元的并购相关费用[119] 业务表现 - 医疗器械分部收入在2024财年第三季度为2340万美元，同比下降49%[130] - 医疗器械产品销售在2024财年第三季度增长15%至1070万美元[130] - 性能涂层专利费和许可费收入在2024财年第三季度增长13%至930万美元[130] - SurVeil DCB许可费收入在2024财年第三季度为110万美元，2023财年第三季度为2590万美元[130] - 体外诊断分部收入在2024财年第三季度增长8%至700万美元[131] - 体外诊断产品销售在2024财年第三季度增长7%至680万美元[131] - 产品毛利在2024财年第三季度增长4%至9114万美元，产品毛利率为51.9%[135] 费用管控 - 研发费用在2024财年第三季度下降13%至9765万美元[136] - 销售及管理费用在2024财年第三季度增长29%至1.66亿美元[137] - 公司在2023财年第二季度实施了裁员计划，在2023财年前九个月计提了1282万美元的重组费用[139] 税务影响 - 公司自2023财年起需要将研发成本资本化并在5年内摊销，这将影响预期的美国联邦和州所得税费用以及未来应付现金税[143] - 自2022年9月30日起，公司已对美国净递延税资产全额计提了估值准备，不再记录与美国税前亏损和增量递延税资产相关的税收抵免[143] 分部业绩 - 医疗器械业务第三季度和前九个月营业亏损分别为230.8万美元和221.0万美元，主要由于SurVeil DCB许可费收入大幅下降[144][145] - 体外诊断业务第三季度和前九个月营业利润分别为315.3万美元和963.3万美元，保持稳定[146][147] 现金流 - 第三季度和前九个月经营活动产生的现金流分别为-341.0万美元和926.4万美元，主要受应收账款和合同资产增加的影响[149][150] - 第三季度和前九个月投资活动产生的现金流分别为-1239.5万美元和-217.0万美元，主要用于购买和到期的可供出售投资[151] 融资情况 - 公司于2023财年第一季度新签了5年期有抵押信贷协议，并提取了2500万美元的定期贷款和500万美元的循环信贷[152] - 公司通过与MidCap签订新的五年期担保信贷协议,获得最高1亿美元的定期贷款和2500万美元的循环信贷额度[154] - 截至2024年6月30日,公司现金余额为3820万美元,加上经营现金流和信贷额度,预计可为2024财年的运营和资本支出提供充足的流动性[156] 未来展望 - 公司预计2024财年销售、一般及管理费用将有所增加,主要是由于并购相关费用以及推进Pounce和Sublime产品商业化[156] - 公司预计2024财年研发费用将保持较高水平,主要用于医疗器械产品开发,包括Pounce和Sublime产品[156] 风险因素 - 公司最大客户为Abbott和Medtronic,分别占2023财年收入的27%和10%[158] - 公司面临一系列风险因素,包括持续亏损、依赖少数大客户、新产品开发和监管审批等[162][163]

财务业绩 - 总收入为3,034万美元，较上年同期下降42%[3,6] - 剔除SurVeil DCB许可费收入后，总收入增长10%至2,920万美元[3,7] - 公司第三季度总收入为3.0341亿美元，同比下降42%[27] - 公司前9个月总收入为9.2851亿美元，同比下降11%[31] - 公司第三季度总收入(不含SurVeil DCB许可费)为8966万美元，同比增长18%[1] 业务分部表现 - 医疗器械业务收入下降49%至2,338万美元，主要由于SurVeil DCB许可费收入下降[6,8] - 体外诊断业务收入增长8%至696万美元[6] - 医疗器械业务收入为2.3383亿美元，同比下降49%，主要由于SurVeil DCB许可费收入大幅下降24.733亿美元[26] - 体外诊断业务收入为6958万美元，同比增长8%[27] - 医疗器械业务收入(不含SurVeil DCB许可费)为2.2249亿美元，同比增长10%[29] - 医疗器械业务前9个月收入为7.1754亿美元，同比下降15%[30] - 体外诊断业务前9个月收入为2.1097亿美元，同比增长6%[31] - 医疗器械业务收入(不含SurVeil DCB许可费)前9个月为2.2249亿美元，同比增长10%[32] - 医疗器械业务分部营业亏损2288万美元，同比下降24065万美元[6] - 体外诊断业务分部营业利润3153万美元，同比增长287万美元[6] 盈利指标 - 产品毛利增长4%至910万美元，产品毛利率为51.9%[9] - 营业成本和费用(不含产品成本)增加13%至2,730万美元，主要由于并购相关费用增加[10] - 非GAAP净亏损390万美元，GAAP净亏损760万美元[11] - 调整后EBITDA为160万美元[12] - 公司第三季度调整后EBITDA为161.4万美元，同比下降22974万美元[9] - 公司前三季度调整后EBITDA为1035.7万美元，同比下降9462万美元[10] - 公司第三季度非GAAP净亏损388万美元，非GAAP每股亏损0.27美元[4] - 公司前三季度非GAAP净亏损280.9万美元，非GAAP每股亏损0.20美元[8] 其他 - SurVeil DCB许可费收入为6856.1万美元，同比增长22%[1] - 公司计划与GTCR公司进行并购[5] - 公司投资收益净额为488万美元[8] - 公司暂停2024财年财务指引，因为正在被GTCR收购[14]

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc. (Nasdaq: SRDX), relating to its proposed sale to GTCR LLC. Under the terms of the agreement, Surmodics, Inc. shareholders will receive $43.00 in cash per share of Surmodic ...

Attorney Advertising. Prior results do not guarantee a similar outcome. SOURCE Rowley Law PLLC NEW YORK, May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquisition of the company by GTCR. Stockholders will receive $43.00 for each share of Surmodics stock that they hold. The transaction is valued at approximately $627 million and is expected to close in the second half of 20 ...

MILWAUKEE, May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Surmodics (Nasdaq: SRDX) for possible breaches of fiduciary duty and other violations of law in its transaction with GTCR. If you own Surmodics common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/surmodics-inc. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout th ...

Thrombectomy Prospects Bright: Surmodics' aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism. The company announced the completion of limited market evaluation and commercial launch of two new mechanical thrombectomy systems for the peripheral venous and arterial vasculatures, the Pounce Venous Thrombectomy System and the Pounce LP (Low Profile) Thrombectomy System during the fiscal second quarter. In January, Surmodics announced the successful ea ...

Surmodics, Inc. (NASDAQ:SRDX) Q2 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Gary Maharaj - President and Chief Executive Officer Timothy Arens - Chief Financial Officer Brooks OÂ'Neil - Lake Street Capital Markets Joseph Conway - Needham & Company Jim Sidoti - Sidoti & Company Mike Petusky - Barrington Research Welcome everyone to SurmodicsÂ' Second Quarter of Fiscal Year 2024 Earnings Call. Please note that this call is being webcast the webcast accessible through Investor Relations section of th ...